View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 19, 2020

Moderna reports positive data from Phase I Covid-19 vaccine trial

Moderna has reported positive interim results from the Phase I clinical trial of its Covid-19 vaccine candidate, mRNA-1273, led by the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID).

The company recorded immunogenicity data for the 25µg and 100µg dose levels following two doses (day 43) and at the 250µg dose level after one dose (day 29).

Results showed dose dependent increases in immunogenicity across the three dose levels, as well as between prime and boost with the 25µg and 100µg dose levels.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena